What are the indications, sizing, implantation approach, and postoperative antiplatelet therapy for the Inspiris Resilia bioprosthetic aortic valve?

Inspiris Resilia Bioprosthetic Aortic Valve: Clinical Management

Postoperative Antiplatelet/Anticoagulation Therapy

For patients receiving the Inspiris Resilia bioprosthetic aortic valve via surgical replacement (SAVR), aspirin 75-100 mg daily is reasonable in the absence of other indications for anticoagulation 1. This represents the standard approach for bioprosthetic surgical valves.

Antithrombotic Options (in order of preference):

Primary recommendation:

• Aspirin 75-100 mg daily - Class 2a recommendation for all bioprosthetic SAVR patients 1

Alternative approach for low bleeding risk patients:

• Warfarin (INR target 2.5) for 3-6 months, then transition to aspirin - Class 2a recommendation 1
• This strategy balances thromboembolism prevention against bleeding risk during the early post-implantation period when thrombotic risk is highest

Critical contraindications:

• DO NOT use rivaroxaban 10 mg + aspirin - this combination is contraindicated (Class 3: Harm) for bioprosthetic valves 1
• DO NOT use dabigatran or other direct oral anticoagulants - not approved for any prosthetic valve 1

Clinical Decision Algorithm:

1. Assess bleeding risk (prior bleeding, age >75, renal dysfunction, concurrent antiplatelet needs)
2. If LOW bleeding risk: Consider warfarin (INR 2.5) for 3-6 months, then aspirin
3. If MODERATE-HIGH bleeding risk OR patient preference: Aspirin 75-100 mg daily from start
4. If atrial fibrillation or other indication for anticoagulation exists: Follow standard anticoagulation guidelines for that indication

---

Indications for Inspiris Resilia Valve

The Inspiris Resilia is indicated for aortic valve replacement in patients requiring bioprosthetic valves, with particular consideration for:

• Patients >65 years (per current ESC/EACTS guidelines for bioprosthetic valves) 2
• Younger patients where the novel Resilia tissue technology (designed to reduce calcification and improve durability) and expandable stent (facilitating future valve-in-valve procedures) offer theoretical advantages 3, 2
• Patients refusing or with contraindications to lifelong anticoagulation required for mechanical valves

The valve has been in full commercial use since 2017 after extensive pre-clinical testing showing superiority to the Perimount valve in animal models 3.

---

Valve Sizing

Proper sizing is critical to optimize hemodynamics and prevent patient-prosthesis mismatch. The Inspiris Resilia valve is available in sizes ranging from 19mm to 29mm.

Sizing principles:

• Measure the aortic annulus using standard surgical techniques (direct measurement after native valve excision)
• Select the largest valve size that fits without forcing or distorting the annulus
• Consider aortic root enlargement if the native annulus would result in significant patient-prosthesis mismatch (effective orifice area index <0.85 cm²/m²) 2
• The expandable stent design facilitates future valve-in-valve TAVR procedures, which should factor into sizing decisions in younger patients 3, 2

---

Implantation Approach

Standard surgical aortic valve replacement technique via median sternotomy with cardiopulmonary bypass is the primary approach.

Technical considerations:

Surgical steps:

1. Standard median sternotomy and aortic cannulation
2. Cardioplegic arrest
3. Aortotomy (typically transverse or oblique)
4. Complete excision of diseased native valve and debridement of calcium
5. Annular sizing
6. Interrupted or continuous suture technique for valve implantation (surgeon preference)
7. The valve features a cloth-covered stent that requires secure fixation to prevent paravalvular leak

Critical pitfall to avoid:

• Transprosthetic cuff leak has been reported between the sewing ring and valve stent post 4. Ensure meticulous suture placement and inspect for leaks before closing.

Concomitant procedures:

• The valve performs well in combined procedures (20% mitral valve surgery, 19% aortic aneurysm repair in large series) 5
• Can be used in reoperations (21% of cases in one series) 5

---

Clinical Performance Data

The Inspiris Resilia demonstrates favorable early-to-midterm outcomes with low reintervention rates 5, 6:

Hemodynamic performance:

• Mean gradient: 12-13 mm Hg at 1-4 years follow-up 5, 6
• 97% of patients have none/trace aortic regurgitation at 4 years 5
• Only 1% have moderate or greater AR at 4 years 5

Safety outcomes (large single-center series, n=3758):

• Operative mortality: 1.2%
• Stroke: 1.3%
• Freedom from reoperation: >95% at 4-5 years 5, 6

Comparative data:

Propensity-matched analysis versus Perimount valve shows:

• Lower likelihood of moderate or greater AR with Inspiris Resilia (p<0.0001) 5
• Similar gradients at 5 years (13.1 vs 13.4 mm Hg) 5, 6
• Similar freedom from reoperation 5, 6

Primary cause of valve failure: Prosthetic valve endocarditis, not structural valve degeneration 5, 6. Only one case of severe structural valve degeneration reported in matched cohorts at 6 years 6.

---

Important Caveats

Longer follow-up is needed - Current data extends to 6 years maximum. The theoretical durability advantages of Resilia tissue require 10-15 year follow-up to confirm 3, 6.

Pulmonary position concerns - Early onset of regurgitation reported when used for pulmonary valve replacement, particularly in native RVOT 7. This valve is optimized for aortic position.

No bridging anticoagulation needed for elective procedures requiring warfarin interruption in bioprosthetic valve patients, unlike mechanical valves 8.